reldesemtiv

Small moleculeexperimental

Clinical trial activity

6 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
5
Phase 3
2
Phase 4
0

Earliest trial started Dec 1, 2015 (NCT02644668)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

NC(=O)c1ccn(-c2cnc(NC[C@]3(c4ncccc4F)C[C@H](F)C3)nc2)c1
Mol. weight
384.39 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ck-2127107

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05442775Phase 3Jul 25, 2022Cytokinetics
NCT04944784Phase 3Aug 16, 2021Cytokinetics
NCT03160898Phase 2Jun 1, 2017Astellas, Cytokinetics
NCT03065959Phase 1May 19, 2017Astellas, Cytokinetics
NCT02662582Phase 2Jun 30, 2016Astellas, Cytokinetics
NCT02644668Phase 2Dec 1, 2015Astellas, Cytokinetics
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CytokineticsFor profit6432015
AstellasFor profit4222015
2 organizations
Page 1 / 1